Advanced Enzyme Technologies Ltd
Advanced Enzyme Technologies Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22). - Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22). - There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24). - Stronger inquiries and interest are seen particularly in the U.S. The company expects a medium to long-term overall revenue growth of 13% to 15% annually over the next 3-5 years.
From Advanced Enzyme Technologies Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22).
- Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22).
- There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24).
- Stronger inquiries and interest are seen particularly in the U.S. marketplace, focusing on enzymes and probiotics segments (Pages 17, 19).
- The company aims to expand into new geographical and application markets, especially in healthcare and biochemical processing, to utilize capacity and grow revenues (Page 17).
- U.S. sales volumes are expected to pick up within the current financial year, aided by improved tariff conditions and increased inquiries (Pages 19, 21).
- R&D and new product launches will support sustained growth (Pages 17, 19).
Profitability & Margins
See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No major CapEx planned for the current fiscal year except for R&D-related investments.
- Upcoming R&D Center in Nashik targeted to be operational by the end of Q2 of the coming year.
- Initial focus of the new R&D Center will be on strain development, protein engineering, and fermentation.
- Larger CapEx of about INR 50 crore anticipated around FY28-29 for greenfield or brownfield expansion.
- Continued efforts to invest in R&D and new product pipelines to support growth and market expansion.
- Strategic investments linked to evolving market opportunities such as healthcare, biochemical processing, and industrial enzymes.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Multiple products are currently under trial with various customers, but specific timelines for outcomes are uncertain; updates expected by Q1 of the next financial year.
- The company is continuously monitoring several pipeline products; some progress quickly while others take longer due to pilot scale and market acceptance processes.
- There is a strong focus on expanding market inquiries, especially in the U.S. for enzymes and probiotics segments, indicating growing interest and potential orders.
- No explicit details on the exact size or value of the current order book or pending orders were provided in the call.
- Management emphasizes a pipeline-driven approach rather than reliance on single-product orders, aiming for steady revenue generation as products mature.
- The outlook includes increased inquiries and interest reflecting a healthier order flow expected in the near to medium term.
Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹203 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Advanced Enzyme's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- OneSource Speci. (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Advanced Enzyme Technologies Ltd Q3 FY26 results?
The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22). - Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22). - There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24). - Stronger inquiries and interest are seen particularly in the U.S. The company expects a medium to long-term overall revenue growth of 13% to 15% annually over the next 3-5 years.
What is Advanced Enzyme Technologies Ltd share price analysis?
Advanced Enzyme Technologies Ltd currently shows a neutral. The stock trades at a P/E of 24.0 with a market cap of ₹3,726 Cr. Investors should review the full earnings analysis for detailed insights.
Is Advanced Enzyme Technologies Ltd planning capital expenditure?
No major CapEx planned for the current fiscal year except for R&D-related investments.
Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.